“…A 10-valent PCV (PCV10; Synflorix TM ) and a 13-valent PCV (PCV13, Prevnar13 TM ) were introduced in Europe in 2009, and resulted in further reductions in IPD [11]. However, since then, the incidence of disease attributable to nonvaccine serotypes has risen, with some serotypes, such as serotypes 3 and 19A persisting [4,11,12] [13], both recently approved for use in adults in the US [14,15]. V114 contains all PCV13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and two additional serotypes, 22F and 33F [16,17].…”